INmune Bio (NASDAQ:INMB) Trading 1.7% Higher – What’s Next?

Shares of INmune Bio, Inc. (NASDAQ:INMB) traded up 1.7% on Tuesday . The company traded as high as $4.93 and last traded at $4.88. 131,907 shares were traded during mid-day trading, a decline of 20% from the average session volume of 165,580 shares. The stock had previously closed at $4.80.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Raymond James started coverage on INmune Bio in a report on Friday, September 27th. They issued an “outperform” rating and a $18.00 target price for the company. Scotiabank started coverage on INmune Bio in a report on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 price objective for the company. Finally, Alliance Global Partners started coverage on INmune Bio in a report on Monday, October 21st. They set a “buy” rating and a $20.00 price objective for the company.

INmune Bio Stock Performance

The firm has a market capitalization of $108.42 million, a P/E ratio of -2.24 and a beta of 1.85. The business has a 50 day simple moving average of $5.35 and a two-hundred day simple moving average of $7.13.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.11). INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 117.48%. During the same period in the prior year, the business earned ($0.48) EPS. On average, equities analysts anticipate that INmune Bio, Inc. will post -2.24 earnings per share for the current fiscal year.

Insider Activity at INmune Bio

In other INmune Bio news, CEO Raymond Joseph Tesi acquired 15,380 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $6.38 per share, for a total transaction of $98,124.40. Following the acquisition, the chief executive officer now owns 1,554,106 shares in the company, valued at $9,915,196.28. This represents a 1.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO David J. Moss acquired 10,000 shares of the company’s stock in a transaction on Monday, September 30th. The stock was acquired at an average price of $5.29 per share, with a total value of $52,900.00. Following the acquisition, the chief financial officer now owns 1,285,869 shares in the company, valued at approximately $6,802,247.01. This trade represents a 0.78 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 33,070 shares of company stock worth $200,087 in the last ninety days. 35.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in INMB. Financial Advocates Investment Management increased its position in INmune Bio by 17.4% during the 3rd quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after buying an additional 2,000 shares in the last quarter. Rhumbline Advisers purchased a new position in INmune Bio during the second quarter valued at $121,000. Jane Street Group LLC purchased a new position in shares of INmune Bio in the third quarter valued at about $79,000. Sanctuary Advisors LLC bought a new stake in shares of INmune Bio in the third quarter worth about $113,000. Finally, Barclays PLC increased its stake in INmune Bio by 601.9% during the third quarter. Barclays PLC now owns 29,044 shares of the company’s stock worth $157,000 after acquiring an additional 24,906 shares during the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.